Filgrastim-mediated neutrophil recovery in @entity1 with XXXX treated with docetaxel and doxorubicin.

@entity1 @entity1398 @entity0
STUDY OBJECTIVES: To study the impact of filgrastim 5 microg/kg given once/day through absolute neutrophil count (ANC) recovery on the duration of grade 4 @entity1398 (ANC < 0.5 x 10(3)/mm3) and time to ANC recovery. Additional objectives were to study the average number of filgrastim injections/cycle required to achieve ANC recovery and differences in outcome by cycle. DESIGN: Combined analysis of two double-blind, randomized, multicenter trials. @entity1 : Two hundred twenty-two @entity1 treated for @entity0 . MEASUREMENTS AND MAIN RESULTS: All @entity1 but one were evaluable for efficacy end points. Mean +/- SD duration of grade 4 @entity1398 was 1.7 +/- 1.3 days in cycle 1; the duration decreased in cycles 2-4 to between 1.0 and 1.2 days. Fifty percent of @entity1 had ANC recovery to 10 x 10(3)/mm3 or greater by day 11 of the cycle, and 90% by day 13, corresponding to 10 and 12 days of filgrastim administration, respectively. Across all cycles, the mean +/- SD number of filgrastim injections/cycle was 10.51 +/- 1.70, with little variation among cycles. CONCLUSION: When filgrastim is administered as recommended, starting 24 hours after chemotherapy and continuing through an ANC of 10 x 10(3)/mm3 or greater, neutrophil recovery is rapid and predictable. Because the first cycle of chemotherapy has the highest rates of @entity1398 and @entity1398 , it seems prudent to administer growth factor support preemptively.
